Adenosine Kinase

Adenosine Kinase

The cytosolic enzyme adenosine kinase (AK) catalyzes the transformation of adenosine into AMP. Adenosine kinase is one potential adenosine regulating agent (ARA) target. Because of its extremely brief plasma half-life (1 s), adenosine is primarily cleared through the activation of adenosine kinases. Increased intracellular adenosine produced as a result of adenosine kinase inhibition leaves the cell through passive diffusion or nucleoside transporters to activate adenosine receptors on nearby cell surfaces. Inhibiting adenosine kinase can therefore serve as a different mechanism for activating adenosine receptors and creating adenosine-related pharmacologies.
An alternative approach is to use adenosine kinase inhibitors (AKIs), which can increase local adenosine levels in a more site- and event-specific manner, elicit the desired pharmacology, and do so with a wider therapeutic window. In the rat maximal electric shock (MES) induced seizure assay, several potent AKIs are demonstrated to exhibit anticonvulsant activity.

Adenosine Kinase related products

Structure Cat No. Product Name CAS No. Product Description
V2588 5-Iodotubercidin (NSC-113939) 24386-93-4 5-Iodotubercidin (also known as NSC 113939, 5-ITu)is a novel and potent adenosine kinase inhibitor with IC50 of 26 nM.
V4402 ABT-702 DIHYDROCHLORIDE 1188890-28-9 ABT-702 dihydrochloride is a novel and potentnon-nucleoside adenosine kinase(AK) inhibitor with IC50of 1.7 nM.
V84285 ABT-702 hydrochloride (Adenosine Kinase Inhibitor hydrochloride) 2624336-92-9
V71235 AK-IN-1 378775-98-5 AK-IN-1 (compound 4072-2732) is an adenosine kinase (AK) inhibitor that is competitive for adenosine (Ado) but not ATP.
Contact Us Back to top